ELUT ELUTIA INC. Insider Trading

Director Guido buys 20,000 ELUT shares at $1.04; stock now $1.02, -69.4% from 52-week high of $3.33.

NEELS GUIDO J purchased 20,000 shares at $1.04 on 2026-01-30, expanding his holdings by 20.3% to 118,750 shares. The company is unprofitable (net income $-3.9M on quarterly revenue of $3.3M) and shrinking (annual revenue growth -1.5%), with a market cap of $661.7K. The stock trades at $1.02 today, down 69.4% from its 52-week high of $3.33, though it has risen 58.6% over the past 30 days. The director's cross-ticker buy history shows poor outcomes: 3 prior purchases averaged -10.8% return over 30 days and -8.0% over 90 days, with a 0% win rate. This purchase follows two prior buys at ELUT on consecutive days (2026-01-28 and 2026-01-29), establishing a pattern of accumulation in a deeply distressed, unprofitable micro-cap amid a long-term downtrend.

Director Kevin Rakin bought 70,000 shares of ELUT at $1.06; post-transaction holdings 196,120 shares (+55.5%)

Director Kevin Rakin purchased 70,000 shares of ELUTIA INC. at $1.06 on 2026-01-30, increasing his holdings by 55.5% from 126,120 to 196,120 shares. The company operates with significant financial headwinds: it posted a net loss of $-3.9M against quarterly revenue of $3.3M and experienced -1.5% annual revenue contraction, with market cap of $661.7K reflecting a micro-cap profile. The stock has declined 69.4% from its 52-week high of $3.33, though it has appreciated 58.6% over the trailing 30 days and 10.9% over 90 days. Rakin's cross-ticker track record shows 1 prior buy with a 30-day return of +57.2%, and his same-ticker history at ELUT shows one prior buy on 2025-12-17 that has returned 57.2% so far, though 90-day outcomes for that trade are not yet measurable. This transaction represents a material increase in concentrated exposure to a financially distressed, thinly-capitalized business.

Director Neels Guido J bought 30,000 shares at $1.06 across 2 transactions totaling $31,800.00

NEELS GUIDO J (Director) executed 2 separate purchases totaling 30,000 shares for $31,800.00 on consecutive days, increasing his holdings by 43.6% from 68,750 to 98,750 shares. The transaction occurred at $1.06 per share while the stock currently trades at $1.05, only 1.0% below the entry point. However, the stock is -68.5% from its 52-week high and the company faces fundamental challenges: it reported a net loss of $-3.8M in the latest quarter, operates unprofitably on a full-year basis, and posted negative annual revenue growth of -1.5%, with a market cap of only $681.1K. Notably, this insider's cross-ticker track record shows 1 prior buy with a 90-day win rate of 0.00% and average 90-day return of -8.0%, suggesting his past open-market purchases have not preceded gains. The recent 30-day price surge of +80.1% provides limited conviction signal given the underlying unprofitability and poor historical outcomes of this insider's prior buying activity.

Director Kevin Rakin bought 50,000 shares of ELUT at $0.52; cluster of 4 other insiders bought within 14 days as stock down 87.8% from 52-week high.

Director Kevin Rakin purchased 50,000 shares at $0.52 on 2025-12-17, increasing his holdings by 18.4% to 322,419 shares total. This transaction is part of a multi-insider buying cluster with 4 other insiders acquiring shares within the past 14 days, suggesting coordinated board-level or management confidence. The context is stark: the stock trades at $0.59, down 87.8% from its 52-week high of $4.84, while the company reports $-3.9M net income on $3.3M revenue (latest quarter) with an undisclosed annual revenue decline of -1.5%. The micro-cap market cap of $382.7K makes the company highly illiquid and distressed. Concurrent buying by multiple insiders during a precipitous drawdown and negative earnings backdrop warrants scrutiny of whether insider purchases reflect contrarian conviction in a turnaround scenario or are instead window-dressing in a terminal decline.

Director Brigid bought 25,000 shares of ELUT at $0.52 on 2025-12-17; cluster of 4 other insiders also bought within 14 days

Director Brigid purchased 25,000 shares at $0.52, increasing her holdings from 2,000 to 27,000 shares (+1250.0% net change). The transaction occurs amid a cluster buy pattern, with 4 other insiders buying the same stock within the past 14 days. Separately, the insider's cross-ticker track record shows 4 prior open-market buys averaging +13.6% over 30 days and +59.5% over 90 days with a 100.00% win rate. However, context is material: ELUTIA INC. has a $3.3M market cap with negative fundamentals (net income of $-3.9M last quarter, annual revenue decline of -1.5%, unprofitable full-year results), and the stock has declined -88.8% from its 52-week high of $4.84 to a current price of $0.54—down -22.4% over 30 days and -50.5% over 90 days. The coordinated insider buying pattern at an economically distressed micro-cap warrants close scrutiny of the transaction context and disclosures.

CFO Ferguson Matthew buys 60,000 shares of ELUT at $0.53; 4 other insiders buying within 14 days amid -88.8% decline from 52-week high.

Matthew acquired 60,000 shares at $0.53 on 2025-12-17, expanding his holdings by 15.5% to 447,110 shares, and now holds them at a current price of $0.54 against a 52-week high of $4.84. The company's most recent quarter reported revenue of $3,323,000 with net income of $-3,868,000, and annual revenue growth declined -1.5% year-over-year. Notably, 4 other insiders also purchased shares within the past 14 days, forming a cluster buy pattern during a period when the stock has fallen -88.8% from its 52-week peak and declined -50.5% over the past 90 days. Matthew's cross-ticker track record shows only 2 prior buys with timing outcomes not yet measurable, and his prior transactions at ELUT (December 1 and 2) likewise remain outcome-unresolved. This cluster activity occurred as the company operates unprofitably, creating an ambiguous signal: coordinated insider purchases at depressed valuations warrant attention, but the absence of positive near-term returns on Matthew's prior acquisitions and the company's deteriorating fundamentals limit clarity on insider conviction.

CEO Mills C Randal bought 3,000 shares of ELUT at $0.51; 4-insider cluster buy amid -50.5% 90-day decline and $-3.9M net loss.

Mills C Randal, President and CEO, purchased 3,000 shares at $0.51 on 2025-12-17, bringing his holdings to 379,204 shares. This transaction occurs within a broader cluster pattern: 4 other insiders bought ELUT shares within the past 14 days. However, context reveals material headwinds. ELUT shares have declined -50.5% over 90 days and trade -88.8% below the 52-week high of $4.84. The company posted a net loss of $-3.9M in the latest quarter against revenue of $3.3M, with annual revenue declining -1.5% year-over-year. The CEO's prior buy at this ticker on 2025-11-13 showed a -7.0% 30-day return. The cluster activity and insider accumulation contrasts sharply with deteriorating financial performance and severe price erosion, warranting scrutiny of the underlying business trajectory.

Director David Colpman bought 12,500 shares of ELUT at $0.51; stock down 88.8% from 52-week high, company unprofitable with -$3.9M net income.

Colpman purchased 12,500 shares at $0.51 on 2025-12-17, increasing his holdings by 67.2% to 31,098 shares. The company faces significant fundamental headwinds: revenue of $3.3M declined 1.5% year-over-year, and the firm posted a net loss of $3.9M in its most recent fiscal year. The stock trades at $0.54, down 88.8% from its 52-week high of $4.84 and down 22.4% over the past 30 days. Notably, a cluster of 4 other insiders also purchased shares within the past 14 days, suggesting coordinated accumulation at depressed levels. However, Colpman's prior cross-ticker buy had a -31.8% average 30-day return, and his one prior purchase at this ticker also showed a -31.8% 30-day outcome, raising questions about the timing and conviction behind accumulation in a fundamentally challenged company at an already volatile price point.

CFO Matthew Ferguson bought 10,000 shares at $0.66 average (2 purchases) as ELUT stock down 86.6% from 52-week high.

Matthew Ferguson, Chief Financial Officer of Elutia Inc., executed 2 separate purchases totaling 10,000 shares (10.0K shares) for $6,610.00 over two consecutive days at prices of $0.65 and $0.67, increasing his holdings by 2.7% to 379,071 shares. This activity occurs in a context of significant stock deterioration: the current price of $0.65 represents an 86.6% decline from the 52-week high of $4.84, a 30-day decline of 30.5%, and a 90-day decline of 67.7%. The underlying business fundamentals remain challenged—the company posted a net loss of $3,868,000.00 in the latest quarter and has negative full-year profitability, with annual revenue contracting 1.5% year-over-year. Without scheduled transaction disclosure (10b5-1 plan flagging) or other context indicating this purchase was pre-planned, the filing itself provides no explicit basis for attributing strategic conviction to this acquisition at current depressed valuations. The transaction's modest scale relative to the insider's growing holdings and the company's deteriorating financial condition warrant observer attention to whether this represents confidence or liquidity management.

ELUT CEO Mills C Randal buys 5,000 shares at $0.60; stock now $0.67, down -86.2% from 52-week high, as company burns cash with -$3.9M net income.

Mills C Randal (President and CEO) purchased 5,000 shares at $0.60 on 2025-11-24, increasing his holdings to 358,785 shares (+1.4%). The timing follows three consecutive open-market buys by this insider at ELUT on 2025-11-13, suggesting a pattern of accumulation in recent weeks. However, the company's fundamentals remain severely distressed: latest quarterly net income was -$3.9M against revenue of $3.3M, and the annual revenue growth stands at -1.5%. The stock has collapsed -86.2% from its 52-week high of $4.84, losing -71.2% over the last 90 days alone. While repeated open-market purchases by the CEO could reflect conviction, the extreme deterioration in stock price, persistent unprofitability, and steep recent declines present a contrasting backdrop that warrants scrutiny of whether management is making informed capital allocation decisions or simply averaging down into a deteriorating position.